KPTI · Quarterly Report (Form 10-Q) · Filed August 13, 2026

Karyopharm Therapeutics Inc — 10-Q exhibit

kpti-ex10_2.htm

Karyopharm Therapeutics Inc on Boardroom Alpha

EX-10.2

Exhibit 10.2

AMENDMENT NO. 5 TO

2022 EQUITY INCENTIVE PLAN OF

KARYOPHARM THERAPEUTICS INC.

In accordance with Section 12(d) of the 2022 Equity Incentive Plan (the “Plan”) of Karyopharm Therapeutics Inc. (the “Company”), the Plan is hereby amended, effective as of the date of approval by the Board of Directors of the Company, as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan):

1. Section 4(a)(1)(A) of the Plan be and hereby is deleted in its entirety and the following is inserted in lieu thereof:

5,406,666 shares of Common Stock; and

2. Except as expressly amended herein, the Plan and all of the provisions contained therein shall remain in full force and effect.

* * *

Approved by the Board of Directors on May 22, 2026

Approved by the Stockholders on ______ __, 202__*

*If stockholder approval is not obtained on or prior to May 31, 2027, then the shares subject to this Amendment shall terminate and shall cease to be available under the Plan; provided, however, that if stockholders approve a lesser number of shares on or prior to May 31, 2027, then the amount listed above shall be reduced to reflect the approval of such lesser number of shares.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer